Log in

NASDAQ:SWTXSpringWorks Therapeutics News Headlines

$25.78
-0.49 (-1.87 %)
(As of 04/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$24.90
Now: $25.78
$27.99
50-Day Range
$20.44
MA: $30.59
$41.21
52-Week Range
$17.02
Now: $25.78
$43.90
Volume70,579 shs
Average Volume185,000 shs
Market Capitalization$1.11 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Headlines

SpringWorks Therapeutics (NASDAQ SWTX) News Headlines

Source:
DateHeadline
Comparing SpringWorks Therapeutics (SWTX) and Its CompetitorsComparing SpringWorks Therapeutics (SWTX) and Its Competitors
www.americanbankingnews.com - April 4 at 1:24 PM
SpringWorks Therapeutics: View Ahead Of 2020 CatalystsSpringWorks Therapeutics: View Ahead Of 2020 Catalysts
seekingalpha.com - April 3 at 1:46 PM
Contrasting SpringWorks Therapeutics (SWTX) & Its RivalsContrasting SpringWorks Therapeutics (SWTX) & Its Rivals
www.americanbankingnews.com - April 3 at 11:28 AM
-$0.35 EPS Expected for SpringWorks Therapeutics (NASDAQ:SWTX) This Quarter-$0.35 EPS Expected for SpringWorks Therapeutics (NASDAQ:SWTX) This Quarter
www.americanbankingnews.com - March 31 at 9:40 AM
SpringWorks Therapeutics (SWTX) vs. Its Competitors Head-To-Head ComparisonSpringWorks Therapeutics (SWTX) vs. Its Competitors Head-To-Head Comparison
www.americanbankingnews.com - March 30 at 4:50 AM
Short Interest in SpringWorks Therapeutics (NASDAQ:SWTX) Declines By 7.8%Short Interest in SpringWorks Therapeutics (NASDAQ:SWTX) Declines By 7.8%
www.americanbankingnews.com - March 29 at 9:46 PM
SpringWorks Therapeutics (NASDAQ:SWTX) Receives Average Recommendation of "Buy" from BrokeragesSpringWorks Therapeutics (NASDAQ:SWTX) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - March 25 at 11:46 PM
SpringWorks Therapeutics (NASDAQ:SWTX) Rating Increased to Buy at HC WainwrightSpringWorks Therapeutics (NASDAQ:SWTX) Rating Increased to Buy at HC Wainwright
www.americanbankingnews.com - March 19 at 9:07 AM
Q1 2020 EPS Estimates for SpringWorks Therapeutics (NASDAQ:SWTX) Lifted by WedbushQ1 2020 EPS Estimates for SpringWorks Therapeutics (NASDAQ:SWTX) Lifted by Wedbush
www.americanbankingnews.com - March 19 at 8:16 AM
Comparing SpringWorks Therapeutics (SWTX) & Its PeersComparing SpringWorks Therapeutics (SWTX) & Its Peers
www.americanbankingnews.com - March 18 at 11:18 PM
SpringWorks Therapeutics Announces Issuance of...SpringWorks Therapeutics Announces Issuance of...
www.benzinga.com - March 18 at 8:58 AM
SpringWorks Therapeutics Announces Issuance of New U.S. Composition of Matter Patent to Polymorphic Form of Nirogacestat, Extending Patent Protection into 2039SpringWorks Therapeutics Announces Issuance of New U.S. Composition of Matter Patent to Polymorphic Form of Nirogacestat, Extending Patent Protection into 2039
finance.yahoo.com - March 18 at 8:58 AM
Comparing SpringWorks Therapeutics (SWTX) & Its RivalsComparing SpringWorks Therapeutics (SWTX) & Its Rivals
www.americanbankingnews.com - March 15 at 3:16 PM
SpringWorks Therapeutics (NASDAQ:SWTX) Posts  Earnings Results, Misses Expectations By $0.03 EPSSpringWorks Therapeutics (NASDAQ:SWTX) Posts Earnings Results, Misses Expectations By $0.03 EPS
www.americanbankingnews.com - March 13 at 3:47 PM
SpringWorks Therapeutics: 4Q Earnings SnapshotSpringWorks Therapeutics: 4Q Earnings Snapshot
finance.yahoo.com - March 13 at 12:14 AM
SpringWorks Therapeutics EPS misses by $0.03SpringWorks Therapeutics EPS misses by $0.03
seekingalpha.com - March 12 at 7:13 PM
SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Business HighlightsSpringWorks Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights
finance.yahoo.com - March 12 at 7:13 PM
Researchers Present Preclinical Data Showing Synergistic Activity of SpringWorks Therapeutics’ Gamma Secretase InhibitorResearchers Present Preclinical Data Showing Synergistic Activity of SpringWorks Therapeutics’ Gamma Secretase Inhibitor
www.bloomberg.com - February 11 at 10:14 PM
SpringWorks Therapeutics Inc.SpringWorks Therapeutics Inc.
www.wsj.com - January 24 at 10:47 PM
Heres Why SpringWorks Therapeutics Climbed 69% in DecemberHere's Why SpringWorks Therapeutics Climbed 69% in December
www.fool.com - January 12 at 5:21 PM
SpringWorks Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare ConferenceSpringWorks Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 6 at 5:08 PM
SpringWorks Therapeutics Announces Initiation of Phase 2b ReNeu Clinical Trial of Mirdametinib in Children and Adults withSpringWorks Therapeutics Announces Initiation of Phase 2b ReNeu Clinical Trial of Mirdametinib in Children and Adults with
www.bloomberg.com - December 26 at 6:16 PM
Hedge Funds Have Never Been This Bullish On SpringWorks Therapeutics, Inc. (SWTX)Hedge Funds Have Never Been This Bullish On SpringWorks Therapeutics, Inc. (SWTX)
finance.yahoo.com - December 16 at 7:08 PM
We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business GrowthWe Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth
finance.yahoo.com - December 13 at 2:01 PM
Researchers Present Preclinical Data Showing Synergistic Activity of SpringWorks Therapeutics’ Gamma Secretase Inhibitor (Nirogacestat) with GlaxoSmithKline’s BCMA Antibody-Drug Conjugate (Belantamab Mafodotin) at the American Society of Hematology (ASH) Annual MeetingResearchers Present Preclinical Data Showing Synergistic Activity of SpringWorks Therapeutics’ Gamma Secretase Inhibitor (Nirogacestat) with GlaxoSmithKline’s BCMA Antibody-Drug Conjugate (Belantamab Mafodotin) at the American Society of Hematology (ASH) Annual Meeting
finance.yahoo.com - December 9 at 1:37 PM
SWTX.OQ - SpringWorks Therapeutics Inc Profile | ReutersSWTX.OQ - SpringWorks Therapeutics Inc Profile | Reuters
www.reuters.com - November 12 at 12:17 PM
SpringWorks Therapeutics Reports Third Quarter 2019 Financial Results and Recent Business HighlightsSpringWorks Therapeutics Reports Third Quarter 2019 Financial Results and Recent Business Highlights
finance.yahoo.com - November 12 at 12:17 PM
BRIEF-Springworks Therapeutics Gets Orphan Drug Label For Neurofibromatosis Type 1 TherapyBRIEF-Springworks Therapeutics Gets Orphan Drug Label For Neurofibromatosis Type 1 Therapy
www.msn.com - October 24 at 11:37 PM
SpringWorks Therapeutics Announces Initiation of Phase 2b ReNeu Clinical Trial of Mirdametinib in Children and Adults with Neurofibromatosis Type 1 (NF1)-Associated Plexiform Neurofibromas (NF1-PN)SpringWorks Therapeutics Announces Initiation of Phase 2b ReNeu Clinical Trial of Mirdametinib in Children and Adults with Neurofibromatosis Type 1 (NF1)-Associated Plexiform Neurofibromas (NF1-PN)
finance.yahoo.com - October 24 at 8:36 AM
This page was last updated on 4/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel